Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Investigational Thiophene Drug Kills Tuberculosis Bacteria by Blocking Mycolic Acid Synthesis

By BiotechDaily International staff writers
Posted on 02 Jul 2013
Print article
An experimental drug prevents growth of the tuberculosis (TB)-causing bacterium, Mycobacterium tuberculosis (Mtb), by blocking the metabolic pathway for synthesis of mycolic acid, which is an essential component of the organism's cell membrane.

The cell envelope of M. tuberculosis is distinctive and is associated with its pathogenicity. Features that are very prominent in the cell envelope are the presence of arabinogalactan-mycolate covalently linked to the cell wall peptidoglycan via a phosphodiester bond located on the inner leaflet of the outer membrane and of a free glycolipid called trehalose dimycolate (TDM), which accumulates in a cord-like fashion on the surface of the cells. This provides a thick layer of lipid on the outer part of the cell and protects the tubercle bacillus from noxious chemicals and the host's immune system. Mycolic acids are the major constituents of this protective layer. They also play other important roles as structural components of the cell wall and envelope. More specifically, the cyclopropane rings in mycolic acids of Mtb contribute to the structural integrity of the cell wall complex and protect the bacillus from oxidative stress (hydrogen peroxide).
Investigators at the University of Medicine and Dentistry of New Jersey (Newark, USA) described a new class of thiophene compounds that killed Mtb by the previously uncharacterized mechanism of Pks13 (polyketide synthase 13) inhibition. The Pks13 enzyme catalyzes the condensation of two fatty acyl chains in the final steps of mycolic acid biosynthesis. Thiophenes are important heterocyclic compounds that are widely employed as building blocks in many agriculture and pharmaceuticals chemicals.

Results reported in the June 16, 2013, online edition of the journal Nature Chemical Biology revealed that treatment of Mtb cultures with an experimental thiophene drug was bactericidal and equivalent to treatment with the first-line drug isoniazid, but was less likely to permit emergent resistance. Combined isoniazid and thiophene treatment resulted in complete inhibition of Mtb growth.

“Mtb is a little ball of soap,” said senior author Dr. David Alland, professor of medicine at the University of Medicine and Dentistry of New Jersey. “This study confirms that M. tuberculosis Pks13 is required for mycolic acid biosynthesis, validates it as a druggable target, and demonstrates the therapeutic potential of simultaneously inhibiting multiple targets in the same biosynthetic pathway.”

Related Links:

University of Medicine and Dentistry of New Jersey



Print article

Channels

Genomics/Proteomics

view channel
Image: Protective telomeres are augmented by freely diffusing telomerase (Photo courtesy of University of Colorado Cancer Center).

Single Molecule Imaging Reveals How Telomerase Finds and Binds to the Telomere

Genomics researchers have combined the CRISPR/Cas9 gene editing technique with advanced single-molecule imaging technology to demonstrate how the enzyme telomerase finds and attaches to the telomere, the... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.